a modern approach to ending cancer mortality.
Test Flexibility
% of Patients w/ctDNA Treatment Remain Relapse Free
Our mission is to leverage biological signalling via molecular-based diagnostics & therapeutics to tackle cancer mortality.
Detect
Cell-free DNA represents the key to unlocking tumour heterogeneity
Our physicians utilize NGS to determine the presence of cancer cells.
Afford
MCED testing costs decreased by >90%
This positive growth directs consumers to more affordable and reliable testing solutions (i.e. $500 reimbursement price).
Cure
Liquid Biopsy>Tissue Biopsy
By implementing liquid biopsy patients are less likely to endure the risk of disease progression through this screening-based technique.
minimally invasive diagnostics
sequencing alone is not enough.
Just sequencing ctDNA mutations alone does not provide an adequate foundation to detect early-onset cancers.
To ensure the viability of cancer screening, combining low-dose CT scanning can directly increase diagnosis detection.
meet the brain behind oncolnyx
CEO & Founder of Oncolnyx
Lauren Pearson is an incoming pre-medical student passionate about healthcare innovation. Her current focus is on molecular diagnostics and primary prevention methodology for patients at risk for cancer.
Current Projects
innovation meets functionality
ctDNA Detection Process
